{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T23:03:06Z","timestamp":1768518186278,"version":"3.49.0"},"reference-count":22,"publisher":"Bentham Science Publishers Ltd.","issue":"21","funder":[{"DOI":"10.13039\/501100003397","name":"Independent Innovation Fund of Huazhong University of science and technology","doi-asserted-by":"publisher","award":["2012QN051"],"award-info":[{"award-number":["2012QN051"]}],"id":[{"id":"10.13039\/501100003397","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CTMC"],"published-print":{"date-parts":[[2020,9,18]]},"abstract":"<jats:sec>\n<jats:title>Aims:<\/jats:title>\n<jats:p>A series of 8-methoxy ciprofloxacin- hydrazone\/acylhydrazone hybrids were evaluated\nfor their activity against a panel of cancer cell lines including HepG2 liver cancer cells, MCF-7, doxorubicin-\nresistant MCF-7 (MCF-7\/DOX) breast cancer cells, DU-145 and multidrug-resistant DU145\n(MDR DU-145) prostate cancer cells to seek for novel anticancer agents.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Ciprofloxacin with excellent pharmacokinetic properties as well as few side effects, is one\nof the most common used antibacterial agents. Notably, Ciprofloxacin could induce cancer cells apoptosis,\nand cell cycle arrest at the S\/G2 stage. The structure-activity relationship reveals that the introduction\nof the methoxy group into the C-8 position of the fluoroquinolone moiety has resulted in a greater\nbinding affinity to the binding site, and 8-methoxy ciprofloxacin derivatives have proved a variety of\nbiological activities even against drug-resistant organisms. However, to the best of our current knowledge,\nthere are no studies that have reported the anticancer activity of 8-methoxy ciprofloxacin derivatives\nso far. Furthermore, many fluoroquinolone-hydrazone\/acylhydrazone hybrids possess promising\nanticancer activity. Thus, it is rational to screen the anticancer activity of 8-methoxy ciprofloxacin derivatives.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>To enrich the structure-activity relationship and provide new anticancer candidates for further\ninvestigations.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>The desired 8-methoxy ciprofloxacin-hydrazone\/acylhydrazone hybrids 5 and 6 were screened\nfor their in vitro anticancer activity against liver cancer cells HepG2, breast cancer cells MCF-7,\nMCF7\/DOX, prostate cancer cells DU-145 and MDR DU-145 by MTT assay.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>Some of 8-methoxy ciprofloxacin-hydrazone hybrids showed potential activity against HepG2,\nMCF-7, MCF-7\/DOX, DU-145 and MDR DU-145 cancer cell lines, low cytotoxicity towards VERO\ncells and promising inhibitory activity on tubulin polymerization.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p> Compounds 5d and 5f showed promising anticancer activity, low cytotoxicity, and potential\ntubulin polymerization inhibitory activity, were worthy of investigation.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Other:<\/jats:title>\n<jats:p> The structure-activity relationship was enriched.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1568026620666200603105644","type":"journal-article","created":{"date-parts":[[2020,6,4]],"date-time":"2020-06-04T05:13:36Z","timestamp":1591247616000},"page":"1911-1915","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Antiproliferative Activity of 8-methoxy Ciprofloxacin-Hydrozone\/Acylhydrazone Scaffolds"],"prefix":"10.2174","volume":"20","author":[{"given":"Li-Ping","family":"Wang","sequence":"first","affiliation":[{"name":"Liyuan Hospital Affiliated To Tongji Medical College, Huazhong University of Science and Technology, Wuhan 100191, Hubei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi","family":"Xu","sequence":"additional","affiliation":[{"name":"College of Pharmaceutical Sciences, Guizhou University of Traditional Chinese Medicine, Guiyang, Guizhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gui-Ying","family":"Deng","sequence":"additional","affiliation":[{"name":"Liyuan Hospital Affiliated To Tongji Medical College, Huazhong University of Science and Technology, Wuhan 100191, Hubei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sha-Li","family":"Xu","sequence":"additional","affiliation":[{"name":"Liyuan Hospital Affiliated To Tongji Medical College, Huazhong University of Science and Technology, Wuhan 100191, Hubei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","year":"2018","unstructured":"International Agency for Research on Cancer. Latest global cancer\ndata: Cancer burden rises to 18.1 million new cases and 9.6 million\ncancer deaths in 2018. Available from: 2018"},{"key":"ref=2","unstructured":"Cancer Tomorrow Available from:, International Agency for Research on Cancer","journal-title":"Cancer Tomorrow Available from:,"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.addr.2017.04.006","volume":"115","author":"Mu L.M.","year":"2017","unstructured":"Mu L.M.; Ju R.J.; Liu R.; Bu Y.Z.; Zhang J.Y.; Li X.Q.; Zeng F.; Lu W.L.; Dual-functional drug liposomes in treatment of resistant cancers. Adv Drug Deliv Rev 2017,115,46-56","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1016\/j.scib.2018.09.024","volume":"63","author":"Zhang L.","year":"2018","unstructured":"Zhang L.; Li Y.; Chen Q.; Xia Y.; Zheng W.; Jiang X.; The construction of drug-resistant cancer cell lines by CRISPR\/Cas9 system for drug screening. Sci Bull (Beijing) 2018,63(21),1411-1419","journal-title":"Sci Bull (Beijing)"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.ejmech.2017.11.082","volume":"143","author":"Zhang G.F.","year":"2018","unstructured":"Zhang G.F.; Zhang S.; Pan B.; Liu X.; Feng L.S.; 4-Quinolone derivatives and their activities against Gram positive pathogens. Eur J Med Chem 2018,143,710-723","journal-title":"Eur J Med Chem"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1016\/j.ejmech.2018.08.095","volume":"157","author":"Gao F.","year":"2018","unstructured":"Gao F.; Wang P.; Yang H.; Miao Q.; Ma L.; Lu G.; Recent developments of quinolone-based derivatives and their activities against Escherichia coli. Eur J Med Chem 2018,157,1223-1248","journal-title":"Eur J Med Chem"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.ejmech.2019.01.017","volume":"165","author":"Gao F.","year":"2019","unstructured":"Gao F.; Zhang X.; Wang T.; Xiao J.; Quinolone hybrids and their anti-cancer activities: An overview. Eur J Med Chem 2019,165,59-79","journal-title":"Eur J Med Chem"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"3005","DOI":"10.1016\/j.bmc.2019.05.038","volume":"27","author":"Suaifan G.A.R.Y.","year":"2019","unstructured":"Suaifan G.A.R.Y.; Mohammed A.A.M.; Fluoroquinolones structural and medicinal developments (2013-2018): Where are we now? Bioorg Med Chem 2019,27(14),3005-3060","journal-title":"Bioorg Med Chem"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.biopha.2018.12.119","volume":"111","author":"Yadav V.","year":"2019","unstructured":"Yadav V.; Talwar P.; Repositioning of fluoroquinolones from antibiotic to anti-cancer agents: An underestimated truth. Biomed Pharmacother 2019,111,934-946","journal-title":"Biomed Pharmacother"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.ejmech.2018.11.032","volume":"162","author":"Xu Z.","year":"2019","unstructured":"Xu Z.; Zhao S.J.; Lv Z.S.; Gao F.; Wang Y.; Zhang F.; Bai L.; Deng J.L.; Fluoroquinolone-isatin hybrids and their biological activities. Eur J Med Chem 2019,162,396-406","journal-title":"Eur J Med Chem"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.ejmech.2018.01.078","volume":"146","author":"Zhang G.F.","year":"2018","unstructured":"Zhang G.F.; Liu X.; Zhang S.; Pan B.; Liu M.L.; Ciprofloxacin derivatives and their antibacterial activities. Eur J Med Chem 2018,146,599-612","journal-title":"Eur J Med Chem"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.ejmech.2017.09.050","volume":"141","author":"Hu Y.Q.","year":"2017","unstructured":"Hu Y.Q.; Zhang S.; Xu Z.; Lv Z.S.; Liu M.L.; Feng L.S.; 4-Quinolone hybrids and their antibacterial activities. Eur J Med Chem 2017,141,335-345","journal-title":"Eur J Med Chem"},{"key":"ref=13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2019.111970","volume":"187","author":"Ahadi H.","year":"2020","unstructured":"Ahadi H.; Emami S.; Modification of 7-piperazinylquinolone antibacterials to promising anticancer lead compounds: Synthesis and in vitro studies. Eur J Med Chem 2020,187","journal-title":"Eur J Med Chem"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1128\/AAC.43.3.661","volume":"43","author":"Zhao B.Y.","year":"1999","unstructured":"Zhao B.Y.; Pine R.; Domagala J.; Drlica K.; Fluoroquinolone action against clinical isolates of Mycobacterium tuberculosis: effects of a C-8 methoxyl group on survival in liquid media and in human macrophages. Antimicrob Agents Chemother 1999,43(3),661-666","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"4478","DOI":"10.1021\/jm00022a013","volume":"38","author":"Sanchez J.P.","year":"1995","unstructured":"Sanchez J.P.; Gogliotti R.D.; Domagala J.M.; Gracheck S.J.; Huband M.D.; Sesnie J.A.; Cohen M.A.; Shapiro M.A.; The synthesis, structure-activity, and structure-side effect relationships of a series of 8-alkoxy- and 5-amino-8-alkoxyquinolone antibacterial agents. J Med Chem 1995,38(22),4478-4487","journal-title":"J Med Chem"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.ejmech.2010.11.023","volume":"46","author":"Feng L.S.","year":"2011","unstructured":"Feng L.S.; Liu M.L.; Zhang S.; Chai Y.; Wang B.; Zhang Y.B.; Lv K.; Guan Y.; Guo H.Y.; Xiao C.L.; Synthesis and in vitro antimycobacterial activity of 8-OCH(3) ciprofloxacin methylene and ethylene isatin derivatives. Eur J Med Chem 2011,46(1),341-348","journal-title":"Eur J Med Chem"},{"key":"ref=17","first-page":"1694","volume":"49","author":"Gao L.Z.","year":"2014","unstructured":"Gao L.Z.; Xie Y.S.; Li T.; Huang W.L.; Hu G.Q.; [Synthesis,\nantitumor activity and SAR of C-3 oxadiazole\nsulfanylacetylhydrazone-substituted fluoroquinolone analogues].  Yao Xue Xue Bao 2014,49(12),1694-1698","journal-title":"Yao Xue Xue Bao"},{"key":"ref=18","first-page":"298","volume":"43","author":"Hu G.Q.","year":"2012","unstructured":"Hu G.Q.; Hou L.L.; Wang G.Q.; Duan N.N.; Wen X.Y.; Cao T.Y.; Synthesis and antitumor and antibacterial activities of fluoroquinolone C-3 isosteres I. Norfloxacin C-3 carbonylhydrazone derivatives. J Chin Pharmaceut Univ 2012,43,298-301","journal-title":"J Chin Pharmaceut Univ"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/1475-2867-13-67","volume":"13","author":"Sun J.P.","year":"2013","unstructured":"Sun J.P.; Shi Z.Y.; Liu S.M.; Kang Y.H.; Hu G.Q.; Huangfu C.S.; Deng J.B.; Liu B.; Trimethoxy-benzaldehyde levofloxacin hydrazone inducing the growth arrest and apoptosis of human hepatocarcinoma cells. Cancer Cell Int 2013,13(1),67-76","journal-title":"Cancer Cell Int"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/aps.2011.158","volume":"33","author":"Shi Z.Y.","year":"2012","unstructured":"Shi Z.Y.; Li Y.Q.; Kang Y.H.; Hu G.Q.; Huang-fu C.S.; Deng J.B.; Liu B.; Piperonal ciprofloxacin hydrazone induces growth arrest and apoptosis of human hepatocarcinoma SMMC-7721 cells. Acta Pharmacol Sin 2012,33(2),271-278","journal-title":"Acta Pharmacol Sin"},{"key":"ref=21","first-page":"35","volume":"44","author":"Xu Q.J.","year":"2013","unstructured":"Xu Q.J.; Hou L.L.; Wu X.K.; Xie S.Q.; Hu G.Q.; Huang W.L.; Synthesis and antitumor activity of ciprofloxacin bis-(C3\/C7 hydrozone)s. J Chin Pharmaceut Univer 2013,44,35-38","journal-title":"J Chin Pharmaceut Univer"},{"key":"ref=22","doi-asserted-by":"publisher","DOI":"10.3390\/molecules22071171","volume":"22","author":"Xu Z.","year":"2017","unstructured":"Xu Z.; Zhang S.; Feng L.S.; Li X.N.; Huang G.C.; Chai Y.; Lv Z.S.; Guo H.Y.; Liu M.L.; Synthesis and in vitro antimycobacterial and antibacterial activity of 8-OMe ciprofloxacin-hydrozone\/azole hybrids. Molecules 2017,22(7)","journal-title":"Molecules"}],"container-title":["Current Topics in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/182465","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/182465\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/182465","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,21]],"date-time":"2021-01-21T11:19:46Z","timestamp":1611227986000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/182465\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,18]]},"references-count":22,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2020,9,18]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1568026620666200603105644","relation":{},"ISSN":["1568-0266"],"issn-type":[{"value":"1568-0266","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9,18]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-02-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-01","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}